Solid Biosciences Inc
SLDB5.900USD
-0.080-1.34%
收盘 12/23, 16:00（美东）报价延迟15分钟
459.51M总市值
亏损市盈率 TTM
关于 Solid Biosciences Inc 公司
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Solid Biosciences Inc简介
公司代码SLDB
公司名称Solid Biosciences Inc
上市日期Jan 26, 2018
CEOCumbo (Alexander)
员工数量100
证券类型Ordinary Share
年结日Jan 26
公司地址500 Rutherford Avenue
城市CHARLESTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02129
电话16173374680
网址https://www.solidbio.com/
公司代码SLDB
上市日期Jan 26, 2018
CEOCumbo (Alexander)
Solid Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
129.65K
-2.47%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
126.69K
+3.74%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
78.52K
+29.32%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
32.91K
+32.75%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
26.66K
+38.27%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
17.77K
+34.30%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+169.09%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
129.65K
-2.47%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
126.69K
+3.74%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
78.52K
+29.32%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
32.91K
+32.75%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
26.66K
+38.27%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
收入明细
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
其他
52.47%
持股股东
持股股东
占比
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
其他
52.47%
股东类型
持股股东
占比
Investment Advisor
38.12%
Hedge Fund
23.54%
Investment Advisor/Hedge Fund
18.55%
Private Equity
15.19%
Venture Capital
7.46%
Research Firm
2.38%
Individual Investor
0.61%
Bank and Trust
0.13%
Pension Fund
0.07%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
245
82.26M
105.58%
-6.26M
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
2023Q2
203
16.54M
84.41%
-1.08M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
11.91M
15.29%
--
--
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.16%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
7.42M
9.52%
--
--
Jun 30, 2025
RA Capital Management, LP
5.81M
7.46%
+100.00
+0.00%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
4.37M
5.61%
+2.45M
+127.89%
Jun 30, 2025
Adage Capital Management, L.P.
6.73M
8.64%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.37M
4.32%
+905.10K
+36.79%
Jun 30, 2025
Vestal Point Capital, LP
1.50M
1.93%
-248.56K
-14.17%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.18M
4.08%
-339.49K
-9.65%
Jun 30, 2025
Citadel Advisors LLC
2.52M
3.24%
+637.41K
+33.80%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Neuroscience and Healthcare ETF
0.52%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
iShares Neuroscience and Healthcare ETF
占比0.52%
iShares Micro-Cap ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
iShares Biotechnology ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
iShares Russell 2000 ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
公告日期
类型
比率
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
常见问题
Solid Biosciences Inc的前五大股东是谁？
Solid Biosciences Inc 的前五大股东如下：
Perceptive Advisors LLC持有股份：11.91M，占总股份比例：15.29%。
Bain Capital Life Sciences Investors, LLC持有股份：7.91M，占总股份比例：10.16%。
Invus Public Equities Advisors, LLC持有股份：7.42M，占总股份比例：9.52%。
RA Capital Management, LP持有股份：5.81M，占总股份比例：7.46%。
BlackRock Institutional Trust Company, N.A.持有股份：4.37M，占总股份比例：5.61%。
Perceptive Advisors LLC持有股份：11.91M，占总股份比例：15.29%。
Bain Capital Life Sciences Investors, LLC持有股份：7.91M，占总股份比例：10.16%。
Invus Public Equities Advisors, LLC持有股份：7.42M，占总股份比例：9.52%。
RA Capital Management, LP持有股份：5.81M，占总股份比例：7.46%。
BlackRock Institutional Trust Company, N.A.持有股份：4.37M，占总股份比例：5.61%。
Solid Biosciences Inc的前三大股东类型是什么？
Solid Biosciences Inc 的前三大股东类型分别是：
Perceptive Advisors LLC
Bain Capital Life Sciences Investors, LLC
Invus Public Equities Advisors, LLC
Perceptive Advisors LLC
Bain Capital Life Sciences Investors, LLC
Invus Public Equities Advisors, LLC
有多少机构持有Solid Biosciences Inc(SLDB)的股份？
截至2025Q3，共有245家机构持有Solid Biosciences Inc的股份，合计持有的股份价值约为82.26M，占公司总股份的105.58%。与2025Q2相比，机构持股有所增加，增幅为0.99%。
哪个业务部门对Solid Biosciences Inc的收入贡献最大？
在FY2023，--业务部门对Solid Biosciences Inc的收入贡献最大，创收--，占总收入的--%。
